A meta-analysis showed that COVID-19 patients with chemosensory disturbances had lower levels of IL-6 than patients without chemosensory disturbances (125); other meta-analyses of studies that examined systemic IL-6 levels are consistent with this result (124, 126). This evidence concerns the gene IL6 and COVID-19.